Form 4: CPRX Director Acquires Shares Post-RSU Vesting
Insider Transaction Report
Catalyst Pharmaceuticals Director David S. Tierney acquired 1,334 shares of common stock following the vesting of restricted stock units.
Summary
- David S. Tierney, a Director of Catalyst Pharmaceuticals, Inc. (CPRX), acquired 1,334 shares of common stock.
- The acquisition occurred on December 29, 2025, as a result of the vesting and conversion of restricted stock units (RSUs).
- Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- The derivative securities vested in equal tranches: 1/3rd on December 27, 2023, 1/3rd on December 27, 2024, and the final 1/3rd on December 27, 2025.
- Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting, with the final tranche delivered on December 29, 2025.
- Following this transaction, David S. Tierney directly beneficially owns 383,314 shares of common stock.
- Additionally, 178,163 restricted stock units remain beneficially owned by the Director.
Sentiment
Score: 6
Explanation: The filing reports a routine vesting and conversion of restricted stock units for a director, which is a standard compensation event and slightly positive due to increased insider ownership.
Positives
- The Director's direct beneficial ownership of common stock increased by 1,334 shares, aligning management interests with shareholders.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may view the increased direct ownership by a director as a positive sign of alignment between management and shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 12/27/2023 | First tranche of derivative securities (Restricted Stock Units) vested. |
| 12/27/2024 | Second tranche of derivative securities (Restricted Stock Units) vested. |
| 12/27/2025 | Final tranche of derivative securities (Restricted Stock Units) vested. |
| 12/29/2025 | Transaction date; 1,334 shares of common stock acquired upon conversion of vested Restricted Stock Units. |
| 12/30/2025 | Signature date of the Reporting Person for the Form 4 filing. |
Recommendation
holdThe filing reports a routine vesting and conversion of restricted stock units for a director, which is a standard compensation event and does not provide new information to alter the investment thesis for Catalyst Pharmaceuticals. It is not a discretionary purchase or sale that would typically signal a change in management's outlook.
Keywords
Catalyst Pharmaceuticals, CPRX, Form 4, Insider Transaction, Restricted Stock Units, Director Stock Acquisition, Equity Compensation, David S. Tierney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.